REMINDER: Our user survey closes TODAY, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,796.00
Ask: 1,796.50
Change: 19.00 (1.07%)
Spread: 0.50 (0.028%)
Open: 1,784.00
High: 1,799.50
Low: 1,780.00
Prev. Close: 1,780.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: FTSE 100 Led Higher By Mining Constituents

Mon, 02nd Jun 2014 16:33

LONDON (Alliance News) - The FTSE 100 started the month on the front foot Monday, closing higher, after a gauge of China's factory activity rose to a five-month high in May, suggesting the world's second-largest economy is stabilising after a subdued start to the year.

China's official manufacturing purchasing managers' index posted its third straight month of improvement in May, rising to 50.8 from 50.4 in April.

"Despite all of the concerns regarding Chinese growth this year, this number has not crossed the line into contraction territory once which may suggest the slowdown hasn't been as bad as first thought," said Craig Erlam, a market analyst at Alpari. "Alternatively, it may just highlight the fact that the survey predominantly covers the larger firms that are supported by the Chinese government, rather than the overall sector right now," he added.

"Whilst this does not completely dispel concerns over the Chinese economy, it is a step in the right direction," said Richard Perry, a market analyst at Hantec Markets.

Anglo American, closing up 2.3%, Rio Tinto, closing up 2.1%, Glencore, closing up 1.4%, and BHP Billiton, closing up 1%, were all big winners in the FTSE 100, while the FTSE 350 mining sector index ended the day up 1.6%.

Overall, the FTSE 100 closed up 0.3% at 6,864.1, the FTSE 250 closed up 0.5% at 16,084.4, while the AIM All-Share index closed down 0.4% at 812.5.

In Europe, stocks closed mixed.

The manufacturing industry across Europe performed slightly worse in May than first thought, as the final Markit service sector PMI's were broadly revised lower. The only major economy to have its economy revised higher was France, but with a reading of 49.6, the French manufacturing sector has been confirmed to be contracting after the initial print of 49.3.

"The disappointing data paints a picture of a sector struggling to generate any sort of traction in recovery," said Markit senior economist Jack Kennedy.

In Germany, the manufacturing sector PMI was a more healthy 52.3 in May, although still lower than the flash estimate of 52.9, and a drop from April's 54.1. The eurozone wide print was also revised slightly lower to 52.2, from the flash estimate of 52.5.

"On balance, newsflow from the Eurozone has proven increasingly disappointing relative to economists’ forecasts over recent months," said DailyFX currency strategist Ilya Spivak. "Such outcomes may amplify speculation about an expansion of European Central Bank stimulus at this week’s policy meeting," he added.

Shortly after the disappointing PMI data, the preliminary reading of German consumer price inflation fell short of economists' forecasts. Europe's largest economy's CPI fell to 0.9% year-on-year in May, down from 1.3% in April and missing the expected rate of 1.1%.

The CAC 40 in Paris closed down 0.1%, while the DAX 30 in Frankfurt closed up 0.1%.

On Wall Street, after a strong start, stocks plummeted following a report by the Institute for Supply Management that showed an unexpected decrease in its reading on US manufacturing activity. The ISM said its manufacturing index dipped to 53.2 in May, down from 54.9 posted in April, and missing economists' estimates for an increase to 55.4.

However, they have since recovered and currently trade close to flat, after the ISM later issued a correction saying that a software error applied last month's seasonal adjustment factor to this month's data. It clarified that the index should have risen to 56.0 in May, which would have come in above the 55.4 expected by economists.

"Overall, based on the corrected survey, it appears that manufacturing activity is still gathering momentum after the winter slowdown," said Paul Ashworth, chief economist at Capital economics.

Meanwhile, the US Markit manufacturing PMI reading for May came in at 56.4, which comfortably beat the 55.4 posted in April and the 55.5 that had been expected by economists.

At the UK equity market close, the DJIA is up 0.1%, the S&P 500 is fractionally higher, while the NASDAQ Composite is down 0.2%.

At the individual UK equity level, but away from the mining sector, pharmaceutical company Shire was among the leading risers in the blue-chip index Monday, closing up 2%. Shares in the company rose after The Times reported that it had secured a USD5 billion credit facility from banks including Citigroup to finance a takeover offer for the US's NPS Pharmaceuticals. Shire is believed to have arranged the deal to buttress its takeover offer for NPS, a developer of drugs for sufferers of a debilitating bowel condition.

Smith & Nephew, closing down 1.9%, was among the index's biggest losers. The medical technology company fell sharply following an extremely strong share price run, which had seen it close the previous three session as the FTSE 100's biggest riser.

The group jumped 9.8% in three days after the Financial Times published an article last Wednesday that suggested that Stryker, a US maker of hip implants and knee replacements, was about to make an unquantified takeover bid for the company. While Stryker quickly denied the rumours, Smith & Nephew's shares still benefited from the speculation.

GlaxoSmithKline was another big loser Monday, ending the day down 0.5%.

The pharmaceutical company has signed a collaboration and licensing agreement with UK-based biotechnology company Adaptimmune Ltd for its cancer programme, a move that comes just weeks after it agreed to sell its own cancer drug business to Novartis as part of a broader asset swap.

Glaxo's deal with the biotechnology company will see the two companies develop and commercialise Adaptimmune's NY-ESO-1 cancer treatment, as well as Adaptimmune's other treatments using its T-cell receptor engineering technology. Adapitmmune said the deal would be worth a potential USD350 million to it over the next seven years.

Still, Glaxo ended the day lower after it said on Sunday that a late stage study of two potential early breast cancer treatments used in combination, lapatinib and trastuzumab, suggested there was no improvement in disease free survival compared to using just trastuzumab.

In the FTSE 250, St Modwen Properties was a big winner, closing up 2.5%. The property company's shares rose after it said that it still expects to report pretax profit for the first half of its financial year significantly up on the year-earlier period, after it continued to perform "strongly" over the past two months.

It said it expects its asset management and added value activities to be reflected positively in half-year valuations, while initial indications point to a rise in market valuations for the first-half of the year compared with November 2013, reflecting improvements in the residential and commercial property markets across the UK.

AIM All-Share listed Bglobal ended the day up 60%. Shares in the company rocketed after it said that it had agreed to sell its Utiligroup Ltd subsidiary for GBP16.1 million in cash to private equity company NorthEdge Capital LLP, and that it plans to return money to shareholders and de-list from AIM once the deal completes.

Bglobal said it expects to have cash balances of GBP16.8 million after the deal completes, and is already talking with its advisors about the most effective way of returning this money to its shareholders. However, it said the deal will have to be approved by its shareholders.

In the forex market, the pound edged lower against its major rivals Monday morning following the release of some weaker-than-expected UK macro economic data, before reclaiming its losses as the day wore on.

Lending data released by the Bank of England shortly after the UK equity market open showed that mortgage approvals dropped to a nine-month low in April, with 62,918 loans approved, down from 66,563 in March and missing economist expectations for 64,750. Mortgage approvals have declined every month this year so far, with the Bank of England unsure as to the exact reason, although there are suggestions that banks began to rein in lending early ahead of the stricter lending rules introduced recently as part of the Mortgage Market Review.

While there are calls from some to the BoE to act to stem the rising UK house prices, they may be less likely to introduce any new measure in light of the already falling mortgage approvals, analysts say.

At the same time, the BoE revealed that the amount borrowed by individuals in the UK dropped to GBP0.67 billion in April from GBP1.03 billion in March, missing economists expectations of a more modest decrease to GBP0.8 billion.

Meanwhile, the UK Markit manufacturing PMI came in as expected at 57.0 in May, slightly lower than the 57.3 recorded in April but still indicating strong growth in the sector.

The euro experienced a similar day Monday. The single currency ticked lower in early trading following the mixed European PMI data, before recovering as the day wore on.

At the UK equity market close, the pound trades at USD1.6752, EUR1.2312, CHF1.5048, and JPY171.380, while the euro trades at USD1.3604, CHF1.2218, and JPY139.160.

In the data calendar Tuesday, Chinese non-manufacturing purchasing managers' index information is released at 0200 BST, with the latest reading of Chinese HSBC manufacturing PMI released at 0245 BST.

UK Nationwide house price data are published at 0700 BST, shortly before the Bank of England credit conditions survey and UK construction PMI information at 0930 BST. Consumer price inflation and unemployment data for the euro zone is released at 1000 BST.

In the US, the ISM New York index is released at 1445 BST, with factory orders data due at 1500 BST.

In the corporate calendar, blue-chip Wolseley releases a trading update, while FTSE 250-listed LondonMetric Property and Pennon Group release full-year results.


By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2024 13:08

UK dividends calendar - next 7 days

Friday 5 April 
BBGI Global Infrastructure SAdividend payment date
Molten Ventures PLCdividend payment date
Pennon Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
Regional REIT Ltddividend payment date
Rights & Issues Investment Trust PLCdividend payment date
Sylvania Platinum Ltddividend payment date
Titon Holdings PLCdividend payment date
Triple Point Energy Transition PLCdividend payment date
Monday 8 April 
Alumasc Group PLCdividend payment date
LondonMetric Property PLCdividend payment date
Redrow PLCdividend payment date
Tuesday 9 April 
CT Global Managed Portfolio Trust PLCdividend payment date
Downing Strategic Micro-Cap Investment Trust PLCdividend payment date
Dunelm Group PLCspecial dividend payment date
Hays PLCdividend payment date
Renishaw PLCdividend payment date
Safestore Holdings PLCdividend payment date
Wednesday 10 April 
Assura PLCdividend payment date
Primorus Investments PLCspecial dividend payment date
Wilmington PLCdividend payment date
Thursday 11 April 
Amedeo Air Four Plus Ltdex-dividend payment date
Athelney Trust PLCdividend payment date
Aviva PLCex-dividend payment date
Balanced Commercial Property Trust Ltdex-dividend payment date
Barratt Developments PLCex-dividend payment date
Begbies Traynor Group PLCex-dividend payment date
Bioventix PLCex-dividend payment date
Blackfinch Spring VCT PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
Caledonia Mining Corpex-dividend payment date
Capital & Regional PLCex-dividend payment date
Chesnara PLCex-dividend payment date
Colefax Group PLCdividend payment date
CT Private Equity Trust PLCex-dividend payment date
Downing Strategic Micro-Cap Investements Trust PLCex-dividend payment date
Driver Group PLCdividend payment date
F&C Investment Trust PLCex-dividend payment date
Foxtons Group PLCex-dividend payment date
Grafton Group PLCex-dividend payment date
GSK PLCdividend payment date
Harbour Energy PLCex-dividend payment date
Hargreaves Services PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
Hunting PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
International Personal Finance PLCex-dividend payment date
International Public Partnerships Ltdex-dividend payment date
ITV PLCex-dividend payment date
Johnson Service Group PLCex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Just Group PLCex-dividend payment date
Kenmare Resources PLCex-dividend payment date
Kerry Group PLCex-dividend payment date
Kings Arms Yard VCT PLCex-dividend payment date
Law Debenture Corp PLCdividend payment date
Lloyds Banking Group PLCex-dividend payment date
Lowland Investment Cos PLCex-dividend payment date
Luceco PLCex-dividend payment date
Man Group PLCex-dividend payment date
Manchester & London Investement Trust PLCex-dividend payment date
Marble Point Loan Financing Ltdex-dividend payment date
Mercantile Investment Trust PLCex-dividend payment date
Mobius Investment Trust PLCex-dividend payment date
MTI Wireless Edge Ltddividend payment date
North American Income Trust PLCex-dividend payment date
Northamber PLCex-dividend payment date
Octopus Apollo VCT PLCex-dividend payment date
Phoenix Group Holdings PLCex-dividend payment date
Reckitt Benckiser Group PLCex-dividend payment date
Ricardo PLCdividend payment date
Savills PLCex-dividend payment date
Schroder Asian Total Return Investment Cos PLCex-dividend payment date
Schroder European Real Estate Investment Trust PLCex-dividend payment date
Scottish American Investment Cos PLCdividend payment date
Smurfit Kappa Group PLCex-dividend payment date
Softcat PLCex-dividend payment date
Somero Enterprises Incex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Synectics PLCex-dividend payment date
TP ICAP Group PLCex-dividend payment date
Trifast PLCdividend payment date
TT Electronics PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.